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1. Introduction 
Primary sclerosing cholangitis (PSC) is a cholestatic disorder of unknown aetiology, 
characterized by inflammation and obliterative fibrosis involving the intrahepatic, 
extrahepatic bile ducts or both (1). It predominates among men and is frequently associated 
with inflammatory bowel diseases, particularly with ulcerative cholitis. Although there are 
animal models of PSC, pathogenesis is still poorly characterized (2). The target of the 
immune reaction is the medium and large bile ducts. Sensitized bile ducts are damaged by 
different immune cells that are activated in the gastro-intestinal tract and lymph nodes. 
Cholangiocytes become activated to express adhesion molecules, inflammatory and 
profibrogenic cytokines, together growth factors that stimulate the production of fibrous 
tissue. 
The diagnosis of PSC is based in patients who present with an alteration of cholestatic 
enzymes on the basis of magnetic resonance (MRN) cholangiography or direct 
cholangiography (ERCP) which show the typical changes of the biliary tree with multifocal 
strictures and segmental dilatation (3).  
PSC, however, is a heterogeneous disease characterized by at least four variants: 
1. “Classical” PSC (involving the intrahepatic, extrahepatic biliary tree or both) 
2. Small-duct PSC 
3. PSC/autoimmune hepatitis (AIH) overlap syndrome 
4. IgG4 associated cholangitis (IAC) 
2. “Classical” PSC  
The diagnostic approach of this variant has been changed over the last years, due to the 
amelioration of radiological techniques. The gold standard is the cholangiography performed 
with MNR or ERCP, showing the typical changes of the biliary tree (3). A recent meta-analysis 
including 6 manuscripts for a total 456 patients, have shown that MRN has a 86% sensitivity 
and 94% specificity for detecting PSC (4). The American Association for the Study of Liver 
Disease (AASLD) recommend against routine liver biopsy for the diagnosis of PSC in patients 
with typical cholangiographic findings (3). A retrospective study performed at the Mayo Clinic 
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in 138 patients with PSC showed that liver biopsy did not add important clinical information, 
with the exception of a small group of patients (1.3%) in whom liver histology was 
fundamental for the diagnosis of the overlap syndrome with AIH (5).  
In 2002 an international group reported on the prognostic of cholangiographic abnormalities 
generating a scoring model based on the assumption that both intra- and extra-hepatic 
lesions of the biliary tree would reflect the disease severity (6). More recently, this model 
was validated in a large cohort of patients with PSC providing a nomogram which may be 
used to predict medium- and long-term prognosis in individual patients with PSC (7). 
Indeed, the imaging techniques have the objective to rule out secondary cholangitis and to 
evaluate cholangiography findings which may be associated with cholangiocarcinoma. 
3. Small-duct PSC 
This is a variant disease characterized by typical cholestatic and histological features of PSC 
but normal bile ducts on cholangiography (8). It is not clear if small-duct PSC represents an 
early onset of the disease or a different entity. However, studies addressing the natural 
history of this variant have shown a better prognosis of small-duct PSC than the large duct 
PSC. In particular, two multicentre studies have been published so far. The first one 
included 33  patients with small-duct PSC and 260 patients with large-duct PSC evaluated in 
Oxford and Oslo with a median follow-up of 106 vs 105 months respectively (9). More 
recently, another European and US study included 83 patients with small-duct PSC and 166 
patients with large-duct PSC with a median follow-up of 11 years (8). Both studies report 
similar conclusions, showing a statistically significant better prognosis for small-duct PSC 
than large-duct PSC patients. 
Liver biopsy is mandatory for the diagnosis of small-duct PSC in patients with a normal 
ERCP or MRN (3). Periductal concentric (“onion-skin”) fibrosis is the classical finding of 
PSC, unless unspecific histological diagnosis include PSC/AIH overlap syndrome, and a 
number of secondary causes of sclerosing cholangitis including eosinophilic cholangitis, 
histiocytosis X, ischemic cholangitis, mastcell cholangiopathy, and bacterial cholangitis. 
4. PSC/AIH overlap syndrome 
This is a disorder mainly described in children and young adults (10-12). Its characteristics 
include clinical, biochemical, and histologic features typical of PSC. Gregorio et al (10) 
identified a 49% prevalence of PSC/AIH overlap syndrome among AIH paediatric patients, 
whereas in adult series it seems to be quite rare. Diagnosis of an overlap syndrome by use of 
the modified AIH score ranges from 1.4 to 12.5-17% (Table 1, ref. 11, 13-16). The reason of 
the higher rate in Italy may be explained with the inclusion in our series of a number of 
patients deriving from a cohort of paediatric series.  
More recently, the King’s group in London defines PSC with strong autoimmune features in 
children as autoimmune sclerosing cholangitis (ASC)(17). In contrast with the male 
overrepresentation in adults, over 50% of paediatric patients with ASC are girls (17). In our 
experience, patients with PSC/AIH overlap syndrome are significantly younger at 
presentation and exhibit significantly higher serum levels of transaminases and IgG than the 
classical PSC group (15). Association with IBD is more common in the group with 
“classical” PSC than PSC/AIH overlap syndrome group (46.4% vs 20%, p<0.01). As 
expected, non organ-specific autoantibodies which represent the hallmarks of autoimmunity 
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are positive in nearly all patients with PSC/AIH overlap syndrome. Some 50% of the 
patients have atypical perinuclear antineutrophil cytoplasmic antibodies (p-ANCAs). In our 
experience the cumulative probability of survival at 20 years was higher in PSC/AIH 
overlap syndrome than in the “classical” PSC (87.5% vs 73.6%) but the difference was not 
statistically significant (16). 
 
Author Country n. of PSC patients % with overlap 
Van Buuren, 200013 Netherlands 113 8% 
Kaya, 200014 USA 211 1.4% 
Floreani, 200015 Italy 41 17% 
Antoniazzi, 201016 Italy 79 12.6% 
Al-Chalaby, 200811 UK 211 6.1% 
Table 1. Diagnosis of AIH/PSC overlap by use of the modified AIH score 
Liver histology is mandatory for the diagnosis of PSC/AIH overlap syndrome. The main 
features include: piecemeal necrosis, lymphocyte rosetting, and moderate or severe 
periportal or periseptal inflammation (15). 
The EASL guidelines recommend a medical treatment for PSC/AIH overlap syndrome with 
ursodeoxycholic acid and immunosuppressive therapy, but is not evidence-based due to 
lack of adequate studies (18).   
In a retrospective study concentrating on the histological features of PSC in children, Batres et 
al report that 45% of 20 patients had variable degrees of interface hepatitis at diagnosis (19). 
5. IgG4-associated sclerosing cholangitis 
This is a distinct form of PSC recently described in the literature, of unknown aetiology and 
characterized by elevated serum IgG4 and infiltration of IgG4-positive plasma cells in bile 
ducts and liver tissue (20). Since the first observations, it became evident that IAC was highly 
associated to autoimmune pancreatitis (AIP) which represents a distinct form of chronic 
pancreatitis occasionally observed in association with Sjogren’s syndrome, primary biliary 
cirrhosis, Crohn’s disease, ulcerative cholitis or other immune-mediated disorders (21). 
Kamisawa et al. reported that tissue infiltration with abundant IgG4-positive cells was a 
characteristic feature not only of AIP but also of other organs involved in AIP (22). The 
clinical profile of IAC include: 1) older age; 2) male gender (in up to 85% of cases); 3) 
presentation with obstructive jaundice; 4) association with AIP in more than 90% of cases; 6) 
abundant IgG4 infiltrate in biopsy duct specimens; 7) normalization of liver enzymes with 
steroids (20). A recent study found serum IgG4 in 9% in a cohort of 127 patients with PSC 
(23). In comparison to patients with PSC and normal levels of IgG4, the former group had 
significantly higher levels of alkaline phosphatise and bilirubin, in addition to higher Mayo 
risk prognostic score (23). Preliminary data suggest that the immunopathogenesis of IAC 
differs from other immune-mediated cholestatic liver disease in that T helper 2 and T 
regulatory cytokines were markedly overexpressed in IAC patients (24). Being apparently 
different from PSC and similar to AIP, sclerosing cholangitis with and without AIP shows a 
clinical response to steroid therapy (25). When intra-pancreatic stenosis is detected with 
imaging procedures, pancreatic cancer shoul be ruled out. For the diagnosis of Ig4-positive 
AIC a liver biopsy with IgG4 immunostaining is needed (26). If stenosis is demonstrated in 
the hepatic hilar region, cholangiocarcinoma should be discriminated by imaging techniques 
and bile duct biopsy (26). 
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6. Pathology findings 
Liver biopsy is recommended for the diagnosis of small-duct PSC, AIH/PSC overlap 
syndrome and IAC. Bile duct biopsy is mandatory to rule out cholangiocarcinoma in any 
form of PSC. Cholangiocarcinoma should be suspected in case of dominant stenosis 
(common bile duct <1.5 mm in diameter or hepatic duct <1 mm)(27) or in case of “tumour” 
appearance in the hilar region (28). 
7. Bile duct biopsy 
The common characteristic in PSC is the fibro-inflammatory involvement of large ducts and 
the infiltration of lymphocytes in small ducts together with the “onion-like” fibrosis 
surrounding the small intra-hepatic ducts. The IAC type shows peculiar characteristics with 
dense infiltration of lymphocytes and IgG4-positive plasma cells with extensive fibrosis and 
obliterative phlebitis (29). In classical PSC the fibrosis is dense and older, whereas in IgG4-
IAC the entire bile duct walls and periductular tissue are affected. Ghezale et al (20) 
reported positive and abundant IgG4 immunostaining (>10 IgG4-positive cell/HPF) of bile 
duct biopsy specimens of bile duct in 88% of patients. The IgG4 immunostaining needs 
further clarification, however; in fact, a recent study by Zhang et al (30) revealed that 23% of 
98 explanted livers with PSC had periductal infiltration with abundant IgG4-positive plasma 
cells (>10/HPF) in the hilar area. 
In the small-duct PSC large bile duct are normal and only changes in the interlobular bile 
ducts are seen, resulting in “normal” findings at cholangiography (31).  
In the AIH/PSC overlap syndrome bile duct biopsy shows similar characteristics than 
“classical” PSC. 
The main histopathological findings are summarized in the table 2. 
 
 Classical  
PSC 
Small duct 
PSC 
AIH/PSC  
overlap 
IgG4-ISC 
LARGE BILE 
DUCTS 
Luminal side 
including 
cholangiocytes 
Normal 
Similar to 
classical PSC 
Whole bile duct walls 
and periductal tissue 
Inflammatory 
Infiltrate Mild Absent Mild 
Abundant infiltrate of 
lymphocytes and IgG4-
positive plasma cells 
Fibrosis Not dense Absent Dense Dense 
Obliterative 
phlebitis 
- - - + 
SMALL BILE 
DUCTS 
 
 
   
Onion skin 
lesions 
+ + + - 
Table 2. Histopathologic features of bile ducts 
8. Liver biopsy 
Histological classification allows to score the disease in four stages (32). Stage 1 is 
characterized by portal oedema, mild portal inflammation, a non destructive cholangitis 
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with infiltration of lymphocytes in the bile duct and ductular proliferation. In stage 2 
(periportal stage) the lesion extends to involve periportal fibrosis. In stage 3 (septal stage) 
bridging fibrous septa develop and bile ducts degenerate and disappear. Stage 4 is 
characterized by cirrhosis. 
Liver changes, however, may be patchy and there is a sampling variability. 
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